CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $29,082,148 | -33.3% | 715,428 | +7.3% | 0.01% | -41.7% |
| Q3 2022 | $43,573,289 | +21.4% | 666,768 | +12.9% | 0.01% | +33.3% |
| Q2 2022 | $35,889,364 | -6.9% | 590,577 | -3.8% | 0.01% | +12.5% |
| Q1 2022 | $38,530,297 | -14.2% | 613,833 | +3.6% | 0.01% | -11.1% |
| Q4 2021 | $44,918,000 | -39.7% | 592,737 | -10.9% | 0.01% | -43.8% |
| Q3 2021 | $74,501,000 | -26.3% | 665,607 | +6.7% | 0.02% | -27.3% |
| Q2 2021 | $101,034,000 | +49.1% | 624,090 | +12.2% | 0.02% | +37.5% |
| Q1 2021 | $67,780,000 | -21.4% | 556,261 | -1.2% | 0.02% | -20.0% |
| Q4 2020 | $86,215,000 | +80.1% | 563,091 | -1.6% | 0.02% | +53.8% |
| Q3 2020 | $47,874,000 | +30.7% | 572,387 | +14.8% | 0.01% | +18.2% |
| Q2 2020 | $36,633,000 | +430.8% | 498,478 | +206.3% | 0.01% | +450.0% |
| Q1 2020 | $6,901,000 | +462.0% | 162,717 | +707.1% | 0.00% | – |
| Q4 2019 | $1,228,000 | +48.7% | 20,160 | 0.0% | 0.00% | – |
| Q3 2019 | $826,000 | – | 20,160 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |